NASDAQ:CMPI - Checkmate Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.50
  • Forecasted Upside: 86.00 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$13.71
▲ +0.21 (1.56%)
1 month | 3 months | 12 months
Get New Checkmate Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMPI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMPI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$25.50
▲ +86.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Checkmate Pharmaceuticals in the last 3 months. The average price target is $25.50, with a high forecast of $32.00 and a low forecast of $19.00. The average price target represents a 86.00% upside from the last price of $13.71.
Buy
The current consensus among 4 investment analysts is to buy stock in Checkmate Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/12/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/11/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2020Jefferies Financial GroupInitiated CoverageBuy$22.00High
i
9/1/2020Bank of AmericaInitiated CoverageNeutral$19.00High
i
9/1/2020BMO Capital MarketsInitiated CoverageOutperform$32.00N/A
i
9/1/2020BTIG ResearchInitiated CoverageBuy$29.00N/A
i
(Data available from 3/6/2016 forward)
Checkmate Pharmaceuticals logo
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor's ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $13.71
$13.22
$14.19

50 Day Range

MA: $14.31
$13.22
$16.50

52 Week Range

Now: $13.71
$8.61
$23.10

Volume

18,548 shs

Average Volume

24,124 shs

Market Capitalization

$295.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Checkmate Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Checkmate Pharmaceuticals in the last twelve months: Bank of America Co., BMO Capital Markets, BTIG Research, Jefferies Financial Group Inc., and Zacks Investment Research.
View the latest analyst ratings for CMPI.

What is the current price target for Checkmate Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Checkmate Pharmaceuticals in the last year. Their average twelve-month price target is $25.50, suggesting a possible upside of 86.0%. BMO Capital Markets has the highest price target set, predicting CMPI will reach $32.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $19.00 for Checkmate Pharmaceuticals in the next year.
View the latest price targets for CMPI.

What is the current consensus analyst rating for Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CMPI will outperform the market and that investors should add to their positions of Checkmate Pharmaceuticals.
View the latest ratings for CMPI.

What other companies compete with Checkmate Pharmaceuticals?

How do I contact Checkmate Pharmaceuticals' investor relations team?

Checkmate Pharmaceuticals' physical mailing address is 245 MAIN STREET 2ND FLOOR, CAMBRIDGE MA, 02142. The company's listed phone number is 617-682-3625. The official website for Checkmate Pharmaceuticals is www.checkmatepharma.com.